Published in J Thromb Haemost on June 01, 2003
Antiangiogenic activity of rPAI-1(23) promotes vasa vasorum regression in hypercholesterolemic mice through a plasmin-dependent mechanism. Circ Res (2011) 0.81
Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies. Oncotarget (2016) 0.80
Fibroblast growth factor-2 is required for vasa vasorum plexus stability in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol (2012) 0.79
Influence of Interleukin-1 Beta on Platelet-Poor Plasma Clot Formation: A Potential Impact on Early Bone Healing. PLoS One (2016) 0.76
Alteration of blood clot structures by interleukin-1 beta in association with bone defects healing. Sci Rep (2016) 0.75
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost (2007) 3.22
Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis. J Lab Clin Med (1992) 2.22
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res (2010) 1.93
Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2). J Thromb Haemost (2007) 1.92
Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood (2000) 1.74
Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost (2008) 1.70
Cavitational mechanisms in ultrasound-accelerated thrombolysis at 1 MHz. Ultrasound Med Biol (2000) 1.55
Ultrasound reversibly disaggregates fibrin fibers. Thromb Haemost (1997) 1.40
Diagnosis of femoropopliteal venous thrombosis with MR imaging: a comparison of four MR pulse sequences. AJR Am J Roentgenol (1990) 1.39
Characterization of ultrasound-potentiated fibrinolysis in vitro. Blood (1993) 1.36
A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg (1994) 1.26
Binding of basic fibroblast growth factor to fibrinogen and fibrin. J Biol Chem (1998) 1.25
Fibrin induces release of von Willebrand factor from endothelial cells. J Clin Invest (1987) 1.22
Enhancement of fibrinolysis with 40-kHz ultrasound. Circulation (1998) 1.19
Enzymatic degradation of the factor-VIII-von-Willebrand protein: a unique tryptic fragment with ristocetin cofactor activity. Blood (1980) 1.18
Rapid lysis of coronary artery thrombi with anisoylated plasminogen: streptokinase activator complex. Treatment by bolus intravenous injection. Ann Intern Med (1986) 1.17
Polonium-210 analyses of vegetables, cured and uncured tobacco, and associated soils. Science (1965) 1.11
Structural studies of the functional heterogeneity of von Willebrand protein polymers. Blood (1981) 1.10
Relationship of the lytic state to successful reperfusion with standard- and low-dose intracoronary streptokinase. Circulation (1985) 1.08
Two-step warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding. JAMA (1983) 1.05
Flow through clots determines the rate and pattern of fibrinolysis. Thromb Haemost (1994) 1.04
Effect of 40-kHz ultrasound on acute thrombotic ischemia in a rabbit femoral artery thrombosis model: enhancement of thrombolysis and improvement in capillary muscle perfusion. Circulation (2000) 1.04
Binding of tissue-plasminogen activator to fibrin: effect of ultrasound. Blood (1998) 1.04
Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med (1983) 1.02
Plasmic degradation of crosslinked fibrin. I. Structural analysis of the particulate clot and identification of new macromolecular-soluble complexes. Blood (1980) 1.02
Ultrasound enhancement of thrombolysis and reperfusion in vitro. J Am Coll Cardiol (1993) 1.01
Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med (2001) 1.00
Anticardiolipin antibodies and recurrent coronary events: a prospective study of 1150 patients. Thrombogenic Factors, and Recurrent Coronary Events Investigators. Circulation (2000) 0.99
Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential. J Lab Clin Med (1992) 0.99
Hemolysis in vivo from exposure to pulsed ultrasound. Ultrasound Med Biol (1997) 0.98
Fibrinogen binding to human blood platelets: effect of gamma chain carboxyterminal structure and length. Blood (1986) 0.98
Transport processes in fibrinolysis and fibrinolytic therapy. Thromb Haemost (1996) 0.97
Structural studies of fibrinolysis by electron microscopy. Blood (1998) 0.97
Low-intensity ultrasound increases endothelial cell nitric oxide synthase activity and nitric oxide synthesis. J Thromb Haemost (2004) 0.97
Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin Thromb Hemost (2001) 0.95
Response of C-reactive protein and serum amyloid A to influenza A infection in older adults. J Infect Dis (2001) 0.95
Challenges of rare disease research: limited patients and competing priorities. Haemophilia (2011) 0.94
Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery. Ann Intern Med (1998) 0.93
Ultrasound increases flow through fibrin gels. Thromb Haemost (1995) 0.93
Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction. J Thromb Haemost (2004) 0.92
Principles of access to health care. Access to Health Care Task Force, American Heart Association. Circulation (1993) 0.92
Cell proliferation on fibrin: modulation by fibrinopeptide cleavage. Blood (1995) 0.92
Neuropathologic findings in a Guillain-Barré patient with strokes after IVIg therapy. Neurology (2002) 0.92
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost (2003) 0.92
Heparin-binding domain of fibrin mediates its binding to endothelial cells. Arterioscler Thromb Vasc Biol (1996) 0.91
Demonstration of a large molecular weight variant of the gamma chain of normal human plasma fibrinogen. J Biol Chem (1980) 0.91
Spreading of platelets on fibrin is mediated by the amino terminus of the beta chain including peptide beta 15-42. Blood (1993) 0.91
Lower risk of thromboembolic disease after total hip replacement with non-cemented than with cemented prostheses. Lancet (1986) 0.90
Concepts of clot lysis. Annu Rev Med (1986) 0.89
Acceleration of fibrinolysis by ultrasound in a rabbit ear model of small vessel injury. Thromb Res (1994) 0.89
Potentiation of endothelial cell proliferation by fibrin(ogen)-bound fibroblast growth factor-2. J Biol Chem (1999) 0.89
Determination of the topology of factor XIIIa-induced fibrin gamma-chain cross-links by electron microscopy of ligated fragments. J Biol Chem (1993) 0.88
Plasmic degradation of crosslinked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure. J Clin Invest (1980) 0.88
Plasmin degradation of cross-linked fibrin. Ann N Y Acad Sci (1983) 0.88
Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med (2001) 0.88
Ultrasound enhancement of rabbit femoral artery thrombolysis. Cardiovasc Surg (1997) 0.87
Quantitation of venous clot lysis with the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradation. Circulation (1990) 0.87
FGF-2 but not FGF-1 binds fibrin and supports prolonged endothelial cell growth. J Thromb Haemost (2003) 0.87
Comparison of structures of various human fibrinogens and a derivative thereof by a study of the kinetics of release of fibrinopeptides. Biochemistry (1984) 0.87
Structural and chromatographic heterogeneity of normal plasma fibrinogen associated with the presence of three gamma-chain types with distinct molecular weights. Biochim Biophys Acta (1983) 0.86
15-deoxy-Delta12,14 prostaglandin J2-induced heme oxygenase-1 in megakaryocytes regulates thrombopoiesis. J Thromb Haemost (2008) 0.86
Endothelial cell spreading on fibrin requires fibrinopeptide B cleavage and amino acid residues 15-42 of the beta chain. J Clin Invest (1992) 0.86
Thrombolytic therapy for acute transmural myocardial infarction. Intracoronary versus intravenous. Am J Med (1984) 0.86
Magnetic resonance imaging of blood and clots in vitro. Invest Radiol (1990) 0.86
Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis. Am J Med (1990) 0.85
Structural studies of fibrinolysis by electron and light microscopy. Thromb Haemost (1999) 0.85
Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia. J Thromb Haemost (2010) 0.85
The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects. PPAR Res (2008) 0.85
Geologic migration potentials of technetium-99 and neptunium-237. Science (1979) 0.85
Megakaryocyte and hepatocyte origins of human fibrinogen biosynthesis exhibit hepatocyte-specific expression of gamma chain-variant polypeptides. Blood (1989) 0.83
The C-terminal sequences of the gamma 57.5 chain of human fibrinogen constitute a plasmin sensitive epitope that is exposed in crosslinked fibrin. Blood (1989) 0.83
Demonstration of in situ fibrin degradation in pathologic thrombi. Blood (1984) 0.83
Embolic complications of calf thrombosis following total hip arthroplasty. J Arthroplasty (1993) 0.82
Effect of acoustic cavitation on platelets in the presence of an echo-contrast agent. Ultrasound Med Biol (1998) 0.82
Mediation of fibrin-induced release of von Willebrand factor from cultured endothelial cells by the fibrin beta chain. J Clin Invest (1989) 0.82
A molecular model of plasmic degradation of crosslinked fibrin. Semin Thromb Hemost (1982) 0.81
Ultrasound accelerates urokinase-induced thrombolysis and reperfusion. Am Heart J (1994) 0.81
Fibrinogen and fibrin protect fibroblast growth factor-2 from proteolytic degradation. Thromb Haemost (2000) 0.81
Physiologic regulation and pathologic disorders of fibrinolysis. Hum Pathol (1987) 0.81
Fibrinogen binding potentiates FGF-2 but not VEGF induced expression of u-PA, u-PAR, and PAI-1 in endothelial cells. J Thromb Haemost (2004) 0.80
Multimer size dependence of von Willebrand factor binding to crosslinked or noncrosslinked fibrin. Blood (1990) 0.80
Reversal of multiorgan system dysfunction in sickle cell disease with plasma exchange. Acta Anaesthesiol Scand (1997) 0.80
Heparin-induced thrombocytopenia. Blood Rev (1999) 0.79
Detection of circulating crosslinked fibrin derivatives by a heat extraction-SDS gradient gel electrophoretic technique. Blood (1979) 0.79
Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction. Circulation (1987) 0.79
Purification and functional characterization of homodimeric gamma B-gamma B fibrinogen from rat plasma. Blood (1993) 0.79
Dose-ranging studies of anisoylated plasminogen streptokinase activator complex. Studies in healthy volunteers and in patients with acute myocardial infarction. Drugs (1987) 0.78
Primary fibrinolysis during supraceliac aortic clamping. J Vasc Surg (1997) 0.78
On the conversion of high molecular weight urokinase to the low molecular weight form by plasmin. Thromb Res (1981) 0.78
Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. A 10-year experience at a single institution. Arch Intern Med (1992) 0.78
Plasminogen depletion during streptokinase treatment or two-chain urokinase incubation correlates with decreased clot lysability ex vivo and in vitro. Thromb Haemost (1993) 0.78
Calcium modulates plasmin cleavage of the fibrinogen D fragment gamma chain N-terminus: mapping of monoclonal antibody J88B to a plasmin sensitive domain of the gamma chain. Biochim Biophys Acta (1996) 0.77
Markers of hemostatic activation in affected coronary arteries during angioplasty. Thromb Haemost (1994) 0.77
Purification of three gamma-chains with different molecular weights from normal human plasma fibrinogen. Biochim Biophys Acta (1984) 0.77
Plasma and platelet fibrinogen differ in gamma chain content. Thromb Haemost (1984) 0.77
Degradation of cross-linked fibrin by human leukocyte proteases. J Lab Clin Med (1986) 0.76
Evaluation of mild bleeding disorders and easy bruising. Blood Rev (1994) 0.76